Technical Analysis for INMB - INmune Bio Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical INMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | -18.37% | |
| Wide Bands | Range Expansion | -18.37% | |
| Up 3 Days in a Row | Strength | -18.37% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Trending on StockTwits | about 1 hour ago | |
| Trending on StockTwits | about 2 hours ago | |
| Lower Bollinger Band Support | about 6 hours ago | |
| Down 2 ATRs | about 6 hours ago | |
| Fell Below Lower Bollinger Band | about 7 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/04/2021
INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immune System Disease Immunotherapy Cancer Treatments Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Mdsc Residual Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immune System Disease Immunotherapy Cancer Treatments Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Mdsc Residual Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.99 |
| 52 Week Low | 2.2 |
| Average Volume | 343,703 |
| 200-Day Moving Average | 11.30 |
| 50-Day Moving Average | 18.87 |
| 20-Day Moving Average | 18.86 |
| 10-Day Moving Average | 17.32 |
| Average True Range | 1.92 |
| ADX | 22.9 |
| +DI | 19.56 |
| -DI | 32.70 |
| Chandelier Exit (Long, 3 ATRs ) | 19.32 |
| Chandelier Exit (Short, 3 ATRs ) | 20.39 |
| Upper Bollinger Band | 22.59 |
| Lower Bollinger Band | 15.13 |
| Percent B (%b) | 0.03 |
| BandWidth | 39.53 |
| MACD Line | -0.64 |
| MACD Signal Line | -0.32 |
| MACD Histogram | -0.32 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.61 | ||||
| Resistance 3 (R3) | 22.06 | 20.43 | 20.57 | ||
| Resistance 2 (R2) | 20.43 | 18.84 | 20.21 | 20.22 | |
| Resistance 1 (R1) | 17.90 | 17.86 | 17.09 | 17.45 | 19.88 |
| Pivot Point | 16.27 | 16.27 | 15.86 | 16.05 | 16.27 |
| Support 1 (S1) | 13.74 | 14.68 | 12.93 | 13.29 | 10.86 |
| Support 2 (S2) | 12.11 | 13.70 | 11.89 | 10.52 | |
| Support 3 (S3) | 9.58 | 12.11 | 10.17 | ||
| Support 4 (S4) | 9.13 |
